FDA approves a second Alzheimer's drug that can modestly slow disease

The drugs can delay symptoms of the disease by a matter of months, but come with potentially dangerous side effects. Example video title will go here for this video Example video title will go here for this video WASHINGTON — U.S. officials have approved another Alzheimer’s drug that can modestly slow the disease, providing a new option for patients in the early stages of the incurable, memory-destroying ailment. The Food and Drug Administration approved Eli Lilly’s Kisunla on Tuesday for mild or early cases of dementia caused by Alzheimer’s. It’s...